Analyst Ratings for Ligand Pharma (LGND)
LGND Rating Summary
LGND Price Target Summary
- Highest: $277.00 (Oppenheimer)
- Lowest: $220.00 (Benchmark)
- Average: $244.71
* Over Last 12-Mos
Overall Rating:
BUY
Rating Trend:
Avg. $ Target:
$244.71 (+21.2%)
* Over Last 12-Mos
Rating Score: 6.8 / 10
Percentile Rank: 74%
Avg. $ Target:
$244.71 (+21.2%)
* Over Last 12-Mos
Rating Score: 6.8 / 10
Percentile Rank: 74%
| Date | Firm | Analyst | Type | Rating (Past) |
PT (Past) |
Start $ (End $) |
% Chg. | Details |
|---|---|---|---|---|---|---|---|---|
| 12/9/2025 | Citi | Yigal Nochomovitz | New Coverage | Buy (N/A) |
270.00 (N/A) |
184.67 (201.90) |
9.33% | Details |
| 4/10/2025 | Stifel » Updated 2/26/2026 |
Annabel Samimy | New Coverage | Buy (N/A) |
230.00 (N/A) |
96.67 (201.90) |
108.85% | Details |
 |
||||||||
|
||||||||
|
||||||||
|
||||||||
|
||||||||
|
||||||||
|
||||||||
|
||||||||
